If Dose 1 eradicates <80% of the treated BE, enrollment in Phase I will continue at the next higher dose (Second Dose). Treatment doses will be escalated in this manner until the first of the therapeutic doses (based on endoscopic exam) is determined, or the incidence of a dose-related Serious Adverse Event (SAE).